Insights From 2025 EASL & AASLD Chronic Hepatitis B Guidelines

05/12/2026

Watch Now

Navigating Non-Adherence and Compliance in Wilson's Disease

05/06/2026

Watch Now

The Multidisciplinary Team: Your Guide to Cirrhosis and Portal Hypertension Care

04/22/2026

Watch Now

Identification and Management of MetALD

04/09/2026

Watch Now

MASLD Disease Burden and Low Awareness 2026

04/09/2026

Watch Now

State of the Art: MASLD in Children

04/09/2026

Watch Now

FAQ: What Are the Current Strategies for Managing Pruritus in Patients With PBC?

02/10/2026

In this educational video, Christopher Bowlus, MD, the Chief of Gastroenterology at the University of California Davis and Lena Valente Professor, provides a comprehensive overview of current pharmacologic and non-pharmacologic strategies for managing pruritus (itch) in patients with Primary Biliary Cholangitis (PBC). He explains why pruritus is one of the most common and under recognized symptoms of PBC, affecting up to 80% of patients, and highlights the importance of proactively asking patients about itch using validated tools such as the Numeric Rating Scale (NRS). The discussion explores how itch impacts quality of life, sleep, and social functioning, and reviews practical assessment strategies in clinical practice. Dr. Bowlus walks through conservative measures, historical therapies such as bile acid sequestrants and antihistamines, and their limitations, before focusing on emerging evidence-based treatments that target the underlying cholestatic mechanisms of itch. He reviews the role of PPAR agonists, including newer agents studied in phase 3 trials, as well as intestinal bile acid transport (IBAT) inhibitors that may soon expand available treatment options. The video concludes with a practical framework for individualized symptom management, emphasizing that effective control of pruritus can meaningfully improve patient outcomes and overall quality of life in PBC.

Watch Now

2026

What Special Considerations Should Be Taken While Managing PBC in Pregnant Patients?

02/03/2026

In this video, Aparna Goel, MD, associate professor of medicine at Stanford University, reviews the impact of pregnancy on primary biliary cholangitis (PBC) and key considerations for managing pregnant patients with autoimmune liver disease. The discussion covers how pregnancy affects PBC laboratory markers, including the limitations of alkaline phosphatase as a biomarker, common symptom changes such as worsening pruritus, and the importance of monitoring bile acids, liver enzymes, and fat-soluble vitamins. Medication safety during pregnancy, including continued use of ursodeoxycholic acid, maternal and fetal risk assessment, monitoring for portal hypertension, and postpartum follow-up are also addressed. This practical overview highlights multidisciplinary care and real-world strategies to support safe maternal and fetal outcomes in women with PBC during pregnancy.

Watch Now

2026

Diet and Lifestyle Modifications in PBC: What Can We Recommend to Our Patients?

08/26/2025

In this practical and patient-focused video, Dr. Nadege Gunn, a hepatologist based in Waco, Texas, shares essential diet and lifestyle strategies for individuals living with Primary Biliary Cholangitis (PBC). Addressing a common question—“What can I eat or do to feel better?”—Dr. Gunn highlights the benefits of a balanced, Mediterranean-style diet rich in fruits, vegetables, nuts, seeds, fish, and olive oil. She emphasizes bone health as a key concern for PBC patients, recommending adequate intake of vitamin D and calcium, resistance-based exercises, and regular weight-bearing activity. The video also stresses the importance of monitoring fat-soluble vitamin levels (A, D, E, and K), avoiding alcohol, and supplementing with a multivitamin if needed. Dr. Gunn further underscores the role of maintaining a healthy weight, staying active, avoiding smoking, and ensuring hepatitis A and B vaccinations to prevent additional liver complications. Whether you're a provider looking to guide patients or someone living with PBC seeking actionable advice, this video offers valuable lifestyle recommendations to help manage the disease and improve overall liver health.

Watch Now

2025

A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature

04/17/2025

In this expert journal club summary, Dr. Meena Bansal—System Chief for the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai and Director of the MASH Center of Excellence—explains the significance of the newly adopted nomenclature for fatty liver disease. She reviews the multi-society Delphi consensus statement that led to the transition from NAFLD/NASH to MASLD/MASH, emphasizing the need to remove stigmatizing language and more accurately reflect the metabolic underpinnings of the disease. Dr. Boshell highlights the international collaboration behind the change, involving 56 countries, patient advocacy groups, and leading researchers. This video explores the rationale behind using the umbrella term “steatotic liver disease,” the inclusion of MetALD to reflect patients with both metabolic dysfunction and alcohol use, and how this new framework supports future research in genomics, proteomics, and precision medicine. Tune in to learn how this global consensus is shaping the future of liver disease classification and clinical trials.

Watch Now

What is the Clinical Profile of Resmetirom, Including Dosing Schedules

04/17/2025

In this clinical overview, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, provides a comprehensive update on Resmetirom — the first FDA-approved therapy for adults with MASH (Metabolic Dysfunction-Associated Steatohepatitis) and moderate to advanced fibrosis (F2–F3). Dr. Brown reviews the approved indication for Resmetirom, explains which patients are eligible for treatment, and offers practical guidance on dosing based on body weight and drug interactions. She also addresses common questions regarding use in patients with thyroid conditions and those already on GLP-1 therapies. With a favorable safety profile and minimal side effects—mainly mild nausea and diarrhea—Resmetirom represents a significant breakthrough in managing progressive liver disease. Learn more about proper dosing strategies, drug interactions (including statin use), and how to identify appropriate patients who may benefit from this liver-targeted therapy.

Watch Now

What is Resmetirom and How Does it Work to Treat MASH?

04/17/2025

Thank you Madrigal for your support on this Medication Review Video Module.

Dr. Reed Hogan, a practicing gastroenterologist in Jackson, Mississippi, shares his clinical experience and insights on Resmetirom, the first FDA-approved therapy for MASH (Metabolic Dysfunction-Associated Steatohepatitis). With over 6,000 patients screened annually in his metabolic and fatty liver clinics, Dr. Hogan highlights the urgent need for effective treatment options in fibrotic liver disease and how Resmetirom is filling that gap. He explains the drug’s novel mechanism of action as a thyroid hormone receptor beta (THR-β) agonist, its ability to reduce triglycerides within liver cells, and its impact on reducing inflammation and fibrosis. Drawing from real-world experience with over 100 patients on therapy, Dr. Hogan discusses the favorable safety profile—primarily mild and self-limited GI side effects—and emphasizes why every liver care provider should be considering Resmetirom as a frontline option beyond lifestyle interventions. Tune in for a practical, expert-led update on one of the most significant advancements in liver disease management in decades.

Watch Now